Daina Graybosch
Stock Analyst at Leerink Partners
(0.79)
# 3,748
Out of 4,835 analysts
115
Total ratings
34.09%
Success rate
-14.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $7.81 | +15.24% | 8 | May 14, 2025 | |
| AFMD Affimed | Downgrades: Market Perform | $5 → $0.39 | $0.28 | +39.78% | 8 | May 13, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $76.06 | +56.46% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.25 | +60.00% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.29 | +241.30% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $58.78 | -33.65% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.69 | +337.96% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.56 | +2,400.00% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.07 | +834.58% | 7 | Jan 6, 2023 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.08 | +332.69% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $8.56 | +343.93% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.89 | +105.66% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $92.77 | +141.46% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.74 | +1,624.14% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.11 | +1,431.53% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.39 | +547.48% | 4 | Feb 25, 2022 |
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $7.81
Upside: +15.24%
Affimed
May 13, 2025
Downgrades: Market Perform
Price Target: $5 → $0.39
Current: $0.28
Upside: +39.78%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $76.06
Upside: +56.46%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.25
Upside: +60.00%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.29
Upside: +241.30%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $58.78
Upside: -33.65%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.69
Upside: +337.96%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.56
Upside: +2,400.00%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.07
Upside: +834.58%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.08
Upside: +332.69%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $8.56
Upside: +343.93%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.89
Upside: +105.66%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $92.77
Upside: +141.46%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.74
Upside: +1,624.14%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.11
Upside: +1,431.53%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.39
Upside: +547.48%